
The FDA authorized the emergency use of Fresenius Propoven 2% Emulsion, which the agency says "may be effective to maintain sedation via continuous infusion in patients greater than 16 years old with suspected or confirmed COVID-19 who require mechanical ventilation in an ICU setting."